PCI The Journeys Within

Current Edition

Frankfurt 2027 – 12/10/26
ramusmedical
Asia Pacific

Astellas’ AML therapy bests chemo in Phase 3 study

In a Phase 3 trial, Astellas’ Xospata improved survival for patients with relapsed or refractory acute myeloid leukemia (AML) compared to chemotherapy, according to ...
Continue Reading →
news

Selumetinib granted US Breakthrough Therapy Designation in neurofibromatosis type 1

AstraZeneca and MSD, Inc., Kenilworth, NJ, US (MSD: known as Merck & Co., Inc. inside the US and Canada) today announced that the US Food and Drug Administration...
Continue Reading →
Europe

Clinical trial finds therapy to be well-tolerated in patients with aggressive brain tumour

A phase I clinical trial that set out to assess the safety of a new combination therapy for a type of aggressive brain tumour has found the treatment to be well tole...
Continue Reading →
news

Triphase Accelerator Initiates Phase 1 Clinical Trial of TRPH-222 in B-cell Lymphoma

Next Generation Antibody-Drug Conjugate Developed Using Catalent’s SMARTag® ADC Technology Toronto, Ontario, and Somerset, N.J. – April 1, 2019 – Triphase Acc...
Continue Reading →
news

FDA warns doctors, myeloma patients of doubled death risk from AbbVie, Roche’s Venclexta

Trial patients receiving benefit from Venclexta can continue taking the drug, the FDA said. (AbbVie) Earlier this month, the FDA halted enrollment in multiple my...
Continue Reading →
Europe

AZ’s Farxiga nabbed its Type 1 nod in EU. But after Zynquista’s rebuff, how will it fare at FDA?

AstraZeneca’s Farxiga just won European Commission approval in Type 1 diabetes, but a tough FDA review lies ahead. (AstraZeneca) AstraZeneca’s Farxiga just won E...
Continue Reading →
Europe

Surgery with ultrasound treats high blood pressure in trial

A minimally invasive surgical procedure that targets nerves leading to the kidneys could one day offer a safe way for some people to reduce their blood pressure med...
Continue Reading →
Europe

Aimmune’s peanut drug moves closer to European market

An experimental peanut allergy drug from Aimmune Therapeutics has met the primary endpoint of a Phase 3 European study, according to topline data released by the com...
Continue Reading →
news

Conatus drug misses goal, hitting NASH stocks

Conatus Pharmaceuticals on Thursday disclosed its lead liver disease drug emricasan missed its primary goal in a Phase 2b study of patients with non-alcoholic steato...
Continue Reading →
Asia Pacific

Forxiga approved in Japan for type-1 diabetes

The Japanese Ministry of Health, Labour and Welfare (MHLW) has approved Forxiga (dapagliflozin) as an oral adjunct treatment to insulin for adults with type-1 diabet...
Continue Reading →
Quotient